Cargando…

A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function

BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [...

Descripción completa

Detalles Bibliográficos
Autores principales: Ermer, James, Corcoran, Mary, Lasseter, Kenneth, Marbury, Thomas, Yan, Brian, Martin, Patrick T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949011/
https://www.ncbi.nlm.nih.gov/pubmed/26926668
http://dx.doi.org/10.1097/FTD.0000000000000296
_version_ 1782443365882658816
author Ermer, James
Corcoran, Mary
Lasseter, Kenneth
Marbury, Thomas
Yan, Brian
Martin, Patrick T.
author_facet Ermer, James
Corcoran, Mary
Lasseter, Kenneth
Marbury, Thomas
Yan, Brian
Martin, Patrick T.
author_sort Ermer, James
collection PubMed
description BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [normal function, mild impairment, moderate impairment, severe impairment/end-stage renal disease (ESRD) not requiring hemodialysis, and ESRD requiring hemodialysis] as estimated by glomerular filtration rate (GFR). Participants with normal and mild to severe renal impairment received 30 mg LDX; blood samples were collected predose and serially for 96 hours. Participants with ESRD requiring hemodialysis received 30 mg LDX predialysis and postdialysis separated by a washout period of 7–14 days. Predialysis blood samples were collected predose, serially for 72 hours, and from the dialyzer during hemodialysis; postdialysis blood samples were collected predose and serially for 48 hours. Pharmacokinetic end points included maximum plasma concentration (C(max)) and area under the plasma concentration versus time curve from time 0 to infinity (AUC(0–∞)) or to last assessment (AUC(last)). RESULTS: Mean LDX C(max), AUC(last), and AUC(0–∞) in participants with mild to severe renal impairment did not differ from those with normal renal function; participants with ESRD had higher mean C(max) and AUC(last) than those with normal renal function. d-amphetamine exposure (AUC(last) and AUC(0–∞)) increased and C(max) decreased as renal impairment increased. Almost no LDX and little d-amphetamine were recovered in the dialyzate. CONCLUSIONS: There seems to be prolonged d-amphetamine exposure after 30 mg LDX as renal impairment increases. In individuals with severe renal impairment (GFR: 15 ≤ 30 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 50 mg/d; in patients with ESRD (GFR: <15 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 30 mg/d. Neither LDX nor d-amphetamine is dialyzable.
format Online
Article
Text
id pubmed-4949011
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-49490112016-08-03 A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function Ermer, James Corcoran, Mary Lasseter, Kenneth Marbury, Thomas Yan, Brian Martin, Patrick T. Ther Drug Monit Original Article BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [normal function, mild impairment, moderate impairment, severe impairment/end-stage renal disease (ESRD) not requiring hemodialysis, and ESRD requiring hemodialysis] as estimated by glomerular filtration rate (GFR). Participants with normal and mild to severe renal impairment received 30 mg LDX; blood samples were collected predose and serially for 96 hours. Participants with ESRD requiring hemodialysis received 30 mg LDX predialysis and postdialysis separated by a washout period of 7–14 days. Predialysis blood samples were collected predose, serially for 72 hours, and from the dialyzer during hemodialysis; postdialysis blood samples were collected predose and serially for 48 hours. Pharmacokinetic end points included maximum plasma concentration (C(max)) and area under the plasma concentration versus time curve from time 0 to infinity (AUC(0–∞)) or to last assessment (AUC(last)). RESULTS: Mean LDX C(max), AUC(last), and AUC(0–∞) in participants with mild to severe renal impairment did not differ from those with normal renal function; participants with ESRD had higher mean C(max) and AUC(last) than those with normal renal function. d-amphetamine exposure (AUC(last) and AUC(0–∞)) increased and C(max) decreased as renal impairment increased. Almost no LDX and little d-amphetamine were recovered in the dialyzate. CONCLUSIONS: There seems to be prolonged d-amphetamine exposure after 30 mg LDX as renal impairment increases. In individuals with severe renal impairment (GFR: 15 ≤ 30 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 50 mg/d; in patients with ESRD (GFR: <15 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 30 mg/d. Neither LDX nor d-amphetamine is dialyzable. Therapeutic Drug Monitoring 2016-08 2016-07-25 /pmc/articles/PMC4949011/ /pubmed/26926668 http://dx.doi.org/10.1097/FTD.0000000000000296 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Article
Ermer, James
Corcoran, Mary
Lasseter, Kenneth
Marbury, Thomas
Yan, Brian
Martin, Patrick T.
A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title_full A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title_fullStr A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title_full_unstemmed A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title_short A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
title_sort single-dose, open-label study of the pharmacokinetics, safety, and tolerability of lisdexamfetamine dimesylate in individuals with normal and impaired renal function
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949011/
https://www.ncbi.nlm.nih.gov/pubmed/26926668
http://dx.doi.org/10.1097/FTD.0000000000000296
work_keys_str_mv AT ermerjames asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT corcoranmary asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT lasseterkenneth asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT marburythomas asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT yanbrian asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT martinpatrickt asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT ermerjames singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT corcoranmary singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT lasseterkenneth singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT marburythomas singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT yanbrian singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction
AT martinpatrickt singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction